Department of Urology and Renal Transplantation, Sanjay Gandhi and Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow (U.P.), 226014, India.
Gene. 2013 Apr 25;519(1):128-34. doi: 10.1016/j.gene.2013.01.025. Epub 2013 Feb 9.
IL-12 and IL-18 are immunomodulatory cytokines that play important roles in host immune response against cancers. Variation in DNA sequence in gene promoter may lead to altered IL-18 production and/or activity, and hence can modulate an individual's susceptibility to BC. To test this hypothesis, we investigated the relationship of IL-18 gene promoter -137 G/C and -607C/A polymorphisms and IL12 (-16974) A/C with the risk of BC in North Indian population. Polymorphisms in IL-18 and IL-12 genes were analyzed in 200 BC patients and 200 age, ethnicity and sex-matched controls, using restriction fragment length polymorphism-polymerase chain reaction (PCR-RFLP) and amplification refractory mutation specific-polymerase chain reaction (ARMS) method. The concentrations of IL-18 in serum were determined by ELISA. Significant association was observed with IL18 (-137) G/C heterozygous genotype (GC) with 1.96 folds risk of BC as well at C allele carrier and variant C allele having 2 fold and 1.6 fold risk for BC respectively. IL18 (-607) C/A, heterozygous CA genotype also showed a high risk (OR=1.59) for BC. While IL12 (-16974) A/C heterozygote genotype and C allele carrier demonstrated reduced risk of BC. Hetero genotype of IL18 (-137) G/C was associated with risk of recurrence (HR=2.35) in superficial BC patients receiving BCG treatment thus showing least survival. The distributions of IL-18 gene haplotypes were not significantly different between patients and controls. Serum IL-18 levels were significantly higher in BC patients than in the healthy subjects (p=0.025). Serum IL-18 levels was also significantly associated with IL18 (-137) G/C in heterozygous genotype (GC) (p=0.048). Our results suggest that IL-18 gene polymorphism contributes to bladder cancer risk whereas IL-12 is protective. A relation between IL18 (-137) G/C in heterozygous genotype with elevated IL-18 serum level and bladder cancer risk has been registered in the present study.
IL-12 和 IL-18 是免疫调节细胞因子,在宿主对癌症的免疫反应中发挥重要作用。基因启动子中 DNA 序列的变异可能导致 IL-18 产生和/或活性的改变,从而可以调节个体对 BC 的易感性。为了验证这一假设,我们研究了 IL-18 基因启动子-137 G/C 和-607C/A 多态性与 IL12(-16974)A/C 与北印度人群 BC 风险的关系。采用限制性片段长度多态性-聚合酶链反应(PCR-RFLP)和扩增受阻突变特异性-聚合酶链反应(ARMS)方法,分析 200 例 BC 患者和 200 例年龄、种族和性别匹配的对照者的 IL-18 和 IL-12 基因多态性。采用 ELISA 法测定血清中 IL-18 浓度。结果显示,IL18(-137)G/C 杂合基因型(GC)与 1.96 倍的 BC 风险相关,C 等位基因携带者和变异 C 等位基因携带者患 BC 的风险分别为 2 倍和 1.6 倍。IL18(-607)C/A 杂合 CA 基因型也显示出较高的 BC 风险(OR=1.59)。而 IL12(-16974)A/C 杂合基因型和 C 等位基因携带者则显示出 BC 风险降低。IL18(-137)G/C 杂合基因型与接受 BCG 治疗的浅表性 BC 患者的复发风险(HR=2.35)相关,因此生存情况最差。患者和对照组之间的 IL-18 基因单倍型分布无显著差异。BC 患者血清 IL-18 水平明显高于健康对照组(p=0.025)。血清 IL-18 水平与 IL18(-137)G/C 杂合基因型(GC)也显著相关(p=0.048)。本研究结果表明,IL-18 基因多态性与膀胱癌风险有关,而 IL-12 则具有保护作用。本研究还记录了 IL18(-137)G/C 杂合基因型与升高的 IL-18 血清水平与膀胱癌风险之间的关系。